Swiss drugmaker Roche is “extremely cautious” on potential mega-mergers and has a pipeline sufficient to sustain growth without large deals like those done recently by rivals, Chairman Christoph Franz told CNBC in an interview on Tuesday.
“We are extremely cautious when it comes to any kind of mega-merger,” Franz said, adding such mergers may sap capital, require energy to combine different cultures and may distract from core activities like research. “We are focusing on targeted ideas outside our company, and then create partnerships, in some cases also do some M&A activities, but this is small- and medium-sized.”
Date: January 28, 2019
Source: Reuters
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.